Short Interest in Compass Therapeutics, Inc. (NASDAQ:CMPX) Increases By 24.6%

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) saw a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 4,610,000 shares, a growth of 24.6% from the February 28th total of 3,700,000 shares. Based on an average daily volume of 1,440,000 shares, the short-interest ratio is presently 3.2 days. Currently, 5.7% of the shares of the company are sold short.

Compass Therapeutics Stock Down 5.0 %

Shares of Compass Therapeutics stock traded down $0.09 during trading on Thursday, reaching $1.61. The company's stock had a trading volume of 1,908,897 shares, compared to its average volume of 806,124. Compass Therapeutics has a 52 week low of $0.77 and a 52 week high of $4.08. The firm has a market cap of $221.94 million, a PE ratio of -4.34 and a beta of 1.19. The business's 50-day moving average price is $2.81 and its 200-day moving average price is $2.11.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). Equities analysts predict that Compass Therapeutics will post -0.36 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on CMPX shares. HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Compass Therapeutics in a research note on Wednesday, January 8th. D. Boral Capital reiterated a "buy" rating and set a $32.00 target price on shares of Compass Therapeutics in a research note on Tuesday. Piper Sandler started coverage on Compass Therapeutics in a research note on Wednesday, February 19th. They issued an "overweight" rating and a $12.00 price target on the stock. Wedbush reaffirmed an "outperform" rating and set a $8.00 price objective on shares of Compass Therapeutics in a research report on Tuesday. Finally, Guggenheim reissued a "buy" rating and issued a $12.00 price objective on shares of Compass Therapeutics in a research report on Wednesday. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $11.63.

Remove Ads

Institutional Investors Weigh In On Compass Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Intech Investment Management LLC bought a new stake in shares of Compass Therapeutics during the 3rd quarter valued at $30,000. Tower Research Capital LLC TRC raised its stake in Compass Therapeutics by 298.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company's stock valued at $25,000 after purchasing an additional 12,917 shares in the last quarter. Independent Advisor Alliance bought a new stake in Compass Therapeutics during the fourth quarter worth about $26,000. BNP Paribas Financial Markets acquired a new stake in Compass Therapeutics during the fourth quarter worth about $27,000. Finally, XTX Topco Ltd acquired a new stake in Compass Therapeutics during the third quarter worth about $37,000. Institutional investors and hedge funds own 68.43% of the company's stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.